Article: Artimplant Interim Report January - March 2009.

VASTRA FROLUNDA, Sweden -- Regulatory News:

Artimplant AB (STO:ARTIB):

* Net revenue for the first quarter amounted to SEK 4.8 million (2.1)* * The net loss for the first quarter totaled SEK 4.5 million (6.2) * Earnings per share for the first quarter amounted to SEK -0.08 (-0.10) * Sales of Artelon[R] Spacer totaled SEK 3.5 million (1.3) * Sales of Artelon[R] Tissue Reinforcement amounted to SEK 1.3 million (0.8) * Spacer agreements with Small Bone Innovations have been made non-exclusive and Artimplant's margin per unit sold has increased significantly

Events after the period-end * The Schulthess Clinic in Zurich has been granted clearance by ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!